Drug Discovery World

JANUARY 16, 2024

Dr Masaru Kanekiyo On Tuesday 6 February at 11.30am, the speaker will be Masaru Kanekiyo, DVM, PhD, Investigator and Chief of Molecular Immunoengineering Section of the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), NIH. See the full programme and register your interest in this event.

Vaccination 64

Vaccination Vaccine Allergies Protein 64

XTalks

FEBRUARY 29, 2024

The lactose free ice cream features Perfect Day’s animal-free whey protein in a delectable chocolate flavor. Notably, the whey protein used by Perfect Day is a recombinant form of traditional dairy protein. Consequently, this version of Breyers ice cream may not be suitable for individuals with dairy allergies.

Protein 59

Protein Branding Packaging Packaging 59

Scienmag

OCTOBER 14, 2020

Animal study shows treatment blocks inflammation and protects lungs without killing the flu virus COLUMBUS, Ohio – The raging lung inflammation that can contribute to death from the flu can be stopped in its tracks by a drug derived from a naturally occurring human protein, a new animal study suggests.

Protein 40

Protein Drugs Allergies Medicine 40

XTalks

MAY 2, 2024

In 2023, the US Food and Drug Administration (FDA) approved a record-breaking 61 drugs, the most in history. Since January, the FDA has already signed off on more than a dozen novel drugs. The agency is reviewing applications for several highly anticipated drugs for approval in 2024.

Drugs 52

Drugs FDA Approval Sales Vaccination 52

Drug Discovery World

JANUARY 21, 2024

Technology is increasingly important to drug discovery. Advances in this area are having a positive effect on both the commercial success of drug discovery and development organisations, as well as benefitting the health and wellbeing of the global population. It is sponsored by Integra Biosciences and Hamamatsu Corporation.

Protein 52

Protein Vaccination Vaccine Development 52

pharmaphorum

AUGUST 7, 2020

Pfizer has signed a multi-year agreement with Gilead to manufacture and supply the COVID-19 antiviral remdesivir, which is also being tested in combination with other drugs in an effort to fight the pandemic. Pfizer will provide contract manufacturing services at its facility in McPherson, Kansas, to supply the drug to Gilead.

Manufacturing 114

Manufacturing Contract Manufacturing Protein Allergies 114

Drug Discovery World

DECEMBER 18, 2023

An effective HIV vaccine may need to prompt strong responses from CD8+ T cells to protect people from acquiring HIV, according to a study from the National Institute of Allergy and Infectious Diseases (NIAID). The post Study suggests ways to improve future HIV vaccine candidates appeared first on Drug Discovery World (DDW).

Vaccination 59

Vaccination Vaccine Allergies Clinical Trials 59

Pfizer

JULY 26, 2022

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. deliesschef. Tue, 07/26/2022 - 17:41.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

XTalks

AUGUST 25, 2023

In the US, the primary agency responsible for regulating allergen labeling on food products is the US Food and Drug Administration (FDA). While this act is intended to make it easier for consumers with food allergies to identify potential allergens in the products they purchase, many believe it falls short.

Allergies 98

Allergies Manufacturing Contamination Production 98

pharmaphorum

APRIL 28, 2021

Sanofi’s much anticipated drug for both haemophilia A and B – fitusiran – could be filed in 2022 despite a problem with blood clots in some patients in late-stage testing. . The RNA interference (RNAi) drug is designed to treat haemophilia A and B patients by suppressing antithrombin (AT), a protein that inhibits blood clotting.

Drugs 52

Drugs Sales Allergies RNA 52

FDA Law Blog

DECEMBER 8, 2022

Food and Drug Administration (FDA) issued two guidance documents, one draft and one final, on food allergen labeling requirements. labeling of major food allergens in bulk foods, dietary supplements, protein-free ingredients, and foods produced through genetic engineering); and. By Sophia R. Gaulkin — Last week, the U.S.

Genetic Engineering 59

Genetic Engineering Containment Cosmetics Protein 59

pharmaphorum

DECEMBER 23, 2021

Children in England with peanut allergies could be among the first in Europe to get access to Aimmune’s oral immunotherapy Palforzia, after the drugmaker agreed a supply deal with NHS England. billion last year, is also developing immunotherapies for other indications including egg and multi-tree nut allergies.

Allergies 117

Allergies Drugs Clinical Trials Clinical Trials 117

Drug Discovery World

MARCH 23, 2023

The study was co-funded by the National Institute of Allergy and Infectious Diseases (NIAID) and led by Mark M Davis, Director of the Stanford Institute for Immunity, Transplantation and Infection and a professor of microbiology and immunology at Stanford University School of Medicine in California.

Immune Response 52

Immune Response Vaccination Vaccine Protein 52

Drug Discovery World

SEPTEMBER 25, 2023

The trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, and will evaluate the investigational vaccine for safety and its ability to elicit an immune response. “An The post Nanoparticle universal flu vaccine enters Phase I trials appeared first on Drug Discovery World (DDW).

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

Drug Discovery World

JANUARY 22, 2024

Sponsored by Integra Biosciences and Hamamatsu Corporation, it will explore technologies being used for drug discovery and how they get from lab to patient. Simon Bushell, SVP of Molecular Discovery at Entact Bio, will present: ‘Proximity-inducing drugs: Using technological innovation to build the next generation of medicine’.

Engineer 59

Engineer Immune Response Drugs Vaccination 59

Scienmag

AUGUST 11, 2020

Antibody that blocks TREM2 protein frees immune cells to reject cancer Credit: William Vermi/Martina Molgora Immunotherapy has revolutionized cancer treatment by stimulating the patient’s own immune system to attack cancer cells, yielding remarkably quick and complete remission in some cases.

Protein 95

Protein Antibody Drugs Allergies 95

Pharmaceutical Technology

AUGUST 5, 2022

As per the prevailing prion theory, a misfolded version of a normal cell-surface protein acts as the chief infectious agent. No progress in drug discovery. “We On the other hand, I think the progress in drug discovery is nil,” comments Requena on the prion disease landscape. And then comes the question of the right target.

Drugs 299

Drugs Protein Vaccination Vaccine 299

Drug Discovery World

MAY 18, 2023

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

XTalks

MAY 17, 2024

Led by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID), World AIDS Vaccine Day emphasizes the importance of awareness and education in the fight against HIV/AIDS. It’s a day to celebrate the scientific strides made towards a vaccine and to remember the work that still lies ahead.

Vaccination 52

Vaccination Vaccine Research Immune Response 52

XTalks

SEPTEMBER 8, 2020

Albany Molecular Research Inc (AMRI), a global provider of advanced drug development and manufacturing solutions, announced that they have signed a supply agreement with AstraZeneca. The genetic material contains SARS-CoV-2 spike protein. Fauci, in a statement. The Phase 3 trial is being implemented as part of Operation Warp Speed.

Manufacturing 83

Manufacturing Vaccination Vaccine Allergies 83

Delveinsight

JANUARY 21, 2021

Drugs that target the cancer-promoting proteins MDM2 and BET have been attempted in acute myeloid leukaemia (AML) and have not been all that effective on their own. The combination appears to work by activation of the tumour-suppressing protein p53, they announced. billion in total for three drugs. Jacob Van Naarden, M.D.,

Research 52

Research Protein Clinical Trials Clinical Trials 52

XTalks

NOVEMBER 30, 2023

In 2022, the US Food and Drug Administration (FDA) granted approval to the medication Sunlenca (lenacapavir) for adults living with multi-drug resistant HIV-1 infection. Developed by Gilead, Sunlenca is the first drug in a novel class known as capsid inhibitors to receive FDA approval for treating HIV-1.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

The Pharma Data

JANUARY 6, 2021

A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures.’ OYA1 was abandoned as a drug candidate for cancer because it had no effect in reducing tumor burden. Bennett et al., ’ (2021) Viruses 13:52 [link]. About OYA1. OYA1 (a.k.a. HHSN272201800013C (S.Y.,

Clinical Trials 40

Clinical Trials Clinical Trials Drugs In-Vitro 40

Delveinsight

AUGUST 27, 2020

The phase 1 study that is being run by the National Institute of Allergy and Infectious Diseases tests three dose levels of the vaccine, mRNA-1273, given in two injections a month apart in 120 adults. Targeted drug combo attacks breast cancer brain metastases in mice.

Vaccination 53

Vaccination Vaccine Research Trials 53

XTalks

DECEMBER 7, 2020

This level of protection far exceeds expectations set by the Food and Drug Administration (FDA) in the US that indicated they would approve a vaccine if it were only 50 percent effective against the virus. Chile announced they plan on testing the drug interferon ? So far, the drug has had mixed results in the treatment of COVID-19.

Vaccination 52

Vaccination Vaccine Development Drugs 52

Drug Discovery World

OCTOBER 21, 2022

Researchers from Boston University’s National Emerging Infectious Diseases Laboratories conducted a study 1 to create a chimeric virus which combined the spike protein of the Omicron variant with the initial Wuhan strain of Covid-19. . The university is now in continued conversation with NIAID leadership and programme officers. .

Research 52

Research Protein Allergies Development 52

Pharmaceutical Technology

DECEMBER 16, 2022

Both vaccines are based on recombinant proteins and attack the parasite during the sporozoite stage. The monoclonal antibody (mAb) CIS43LS, derived from the antibody CIS43, targets the Plasmodium falciparum circumsporozoite protein (PfCSP), and is being studied by the National Institute of Allergy and Infectious Diseases (NIAID).

Development 264

Development Drugs Vaccination Vaccine 264

Pfizer

JANUARY 27, 2023

Working with collaborators, we have conducted research where the original SARS-CoV-2 virus has been used to express the spike protein from new variants of concern. Report vaccine side effects to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) Vaccine Adverse Event Reporting System (VAERS).

Research 112

Research Vaccination Vaccine Drugs 112

Drug Discovery World

FEBRUARY 26, 2024

The US Food and Drug Administration (FDA) has approved monoclonal antibody Xolair (omalizumab) for immunoglobulin E-mediated food allergy in some adults and children one year or older for the reduction of allergic reactions (Type I).

FDA Approval 52

FDA Approval Allergies Protein Antibody 52

Drug Discovery World

DECEMBER 6, 2022

The team combined scientists from Scripps Research, IAVI, Fred Hutchinson Cancer Center (Fred Hutch) and the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC). .

Vaccination 52

Vaccination Vaccine Trials Antibody 52

XTalks

DECEMBER 24, 2020

From rare disease drug approvals to treatments involving immunotherapies and gene therapies and awarding of a Nobel Prize to the inventors of the gene-editing tool CRISPR, 2020 was a year of great activity and productivity despite the backdrop of the pandemic. Drugs, Testing and Vaccines.

Life Science 111

Life Science Vaccination Vaccine Gene 111

XTalks

AUGUST 2, 2023

Pfizer’s Top 5 Best-Selling Drugs of 2022: 1) Comirnaty Comirnaty is an mRNA-based vaccine indicated for the prevention of COVID-19. Comirnaty was first approved by the US Food and Drug Administration (FDA) in August 2021 for individuals over the age of 16. billion the drug generated in 2021. billion in 2022. billion, a 26.55

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

FEBRUARY 4, 2021

Abionic first developed abioSCOPE in 2010 for allergy testing, and subsequently for sepsis and infection. Dr. Durand explains how “Abionic started with allergy testing [and] also developed tests for iron deficiency and other things. For sepsis, a commercial immunoassay pancreatic stone protein (PSP) test is utilized.

Allergies 98

Allergies Bacteria Development Containment 98

The Pharma Data

MAY 27, 2022

Food and Drug Administration is providing an update on additional steps it has taken that will lead to more infant formula on U.S. million cans of several varieties of its infant formula such as stage 1 and 2 cans of Bubs Organic Grass Fed, Bubs Supreme A2 Beta-Casein Protein and Bubs Easy-digest Goat Milk, that will make at least 27.5

Production 52

Production Manufacturing Cosmetics Allergies 52

The Pharma Data

MAY 15, 2021

Page 84 – Discover what one doctor did to get 70 percent of his patients opening of their clogged arteries and off of drugs or surgery, in mere weeks. Page 152 – The one vitamin which has been shown to naturally normalize cholesterols levels within 3 weeks, without drugs or pills.

Doctors 52

Doctors Doctor Containment Allergies 52

XTalks

OCTOBER 26, 2023

The US Food and Drug Administration (FDA) approved new updated COVID-19 vaccines from both Pfizer-BioNTech and Moderna that target the Omicron XBB.1.5 This means COVID-19 can quickly produce viral proteins once inside the host cell, which may make its replication cycle faster than influenza.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

The Pharma Data

MARCH 24, 2021

The primary analysis is pre-specified in the protocol and will be the basis for a regulatory submission for Emergency Use Authorization to the US Food and Drug Administration in the coming weeks. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

Radiology 52

Radiology Vaccination Vaccine Trials 52